



NeurAegis and Nanosyn announce partnership agreement

NeurAegis announced it has chosen Nanosyn to lead its chemistry efforts towards advancing novel and selective calpain-2 inhibitors to clinical candidates.

POMONA, CALIFORNIA, UNITED STATES, May 31, 2017 /EINPresswire.com/ -- NeurAegis and Nanosyn announce partnership agreement

May 30th, 2017. Pomona, CA and Santa Clara, CA

NeurAegis today announced that it has chosen Nanosyn, Inc., a leading US-based contract research provider of [drug discovery](#) and development services, to lead its chemistry efforts towards advancing novel and selective calpain-2 inhibitors to clinical candidates.

NeurAegis has identified calpain-2 as a critical target in the pathway leading to neuronal death in a variety of neurological disorders resulting from insults or trauma, including traumatic brain injury and concussion, stroke, glaucoma, and other diseases associated with neuronal damage.

Dr. Baudry, NeurAegis CEO said "Nanosyn has an excellent track record in projects delivery. This partnership, combining NeurAegis' team of biologists, chemists and biotech leaders with a company with a proven record of advancing molecules to the clinic, provides for a unique synergy, which will speed up our efforts to develop the best selective calpain-2 inhibitor for [neuroprotection](#)."

"We are excited about this project and look forward to working with NeurAegis' reputable team. Together we are well positioned to develop a new generation of much needed therapies for the patients with neurological disorders", said Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc.

NeurAegis also added Drs. Norton Peet and Shujaath Mehdi to its Scientific Advisory Board.

Dr. Norton Peet

Dr. Norton Peet is an International R&D Consultant, and provides guidance and direction to industrial and academic organizations on drug discovery and development strategies. Dr. Peet currently serves as the Chief Scientific Officer for Chicago BioSolutions, a newly formed drug discovery company. In prior positions, Dr. Peet was Head of Medicinal Chemistry at Microbiotix, where he designed the chemistry for all internal and external research proposals. Dr. Peet is an organic chemist by training (UNL, MIT) and has spent much of his career in big pharma, with the string of companies that led to Aventis (now Sanofi). When he left Aventis in 2000 he was Head of Medicinal Chemistry and Distinguished Scientist. He joined the executive team at ArQule as Vice President of Discovery Alliances, where he managed alliances with several companies and also built a multidisciplinary Drug Discovery Group. In 2002, he became the CEO of Aurigene Discovery Technologies, a drug discovery company, and built laboratories in Boston (Lexington) and Bangalore (India). Dr. Peet has authored 175 journal articles and 70 US patents, and has contributed to 25 awarded grant applications. He has organized numerous international symposia and serves on several editorial and scientific advisory boards.

Dr. Shujaath Mehdi

Dr. Shujaath Mehdi is an expert in enzyme mechanisms and kinetics, in molecular aspects of drug design, discovery and development, and in translational medicine. Dr. Mehdi joined Merrell Dow (a predecessor company of Sanofi) in 1985 in Discovery Research after post-doctoral training in enzymology at Harvard University. Over the years he held the positions of Project Team Leader, Lab

Head, and Group Leader of the Enzyme Chemistry group. Dr. Mehdi was instrumental in the design and characterization of enzyme inhibitors as drugs in multiple therapeutic areas. Prior to retirement, Dr. Mehdi led a cross-functional Translational Medicine group, whose responsibility was to apply translational principles to ensure the success of preclinical and clinical projects in the Immunoinflammation therapeutic area. After retirement from Sanofi in 2012 as a Distinguished Scientist, Dr. Mehdi has taught courses on 'Drug Discovery Through Preclinical Development' and on 'Ethics of Science and Technology Management' in the Master of Business and Science program at Rutgers University, and has lectured on Personalized Medicine at Rutgers and at Columbia University. He is the author of 50 publications, and is the co-inventor of 17 US Patents.

About NeurAegis

NeurAegis (www.neuraegis.com) has been founded to translate fundamental discoveries on the mechanisms of synaptic plasticity and neuronal survival/cell death into clinical applications. NeurAegis has identified neuroprotection as a key focus for research and development, because of the high unmet needs and tremendous research potential in this therapeutic area. Nevertheless, there is still no drug on the market that provides any significant degree of neuroprotection, especially within the crucial minutes to maximum of several hours following any brain insult that results in neuronal loss. NeurAegis company is privately held and self-funding. The company has laboratories in Pomona, CA.

Contact information: Michel Baudry, CEO, NeurAegis: m.baudry@neuraegis.com; tel: 949-468-7310.

About Nanosyn

Nanosyn (www.nanosyn.com) is a Contract Research and Manufacturing Organization providing integrated drug discovery and development services, medicinal chemistry, process chemistry, cGMP manufacturing, assay development, screening and profiling services, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is privately held and self-funding. The company is headquartered in San Francisco Bay Area, California with discovery site in Santa Clara, CA and cGMP kilo lab in Santa Rosa, CA.

Contact information: Olga Issakova, Executive VP, Nanosyn: oissakova@nanosyn.com; tel: 650-269-3528

Michel Baudry
NeurAegis
9094698271
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.